Conditionally Immortalized Stem Cells for Scalable Microparticle Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies face challenges such as the need for a consistent and substantial supply of stable stem cells, high costs, immunological compatibility issues, and regulatory concerns related to tumour or ectopic tissue formation, as well as limited therapeutic efficacy and scalability of stem cell-derived exosomes.
Innovation Solution
Conditionally-immortalised cells, such as neural stem cells and mesenchymal stem cells, are used to produce microparticles like exosomes, which are harvested from conditioned media, allowing for continuous production and overcoming the limitations of traditional stem cell therapies by providing a stable and scalable source of therapeutically useful microparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional stem cells are used to produce microparticles, then therapeutic efficacy is maintained, but production consistency and scalability are limited
Solution Approach 1:
The patent applies parameter changes by modifying the stem cell state through conditional immortalization. The cells are transformed from a finite, hard-to-expand state to an immortalized state that enables continuous culture and large-scale production. This parameter change in cell longevity and expandability directly resolves the contradiction between production scalability and therapeutic efficacy, as the immortalized cells maintain the ability to produce therapeutically active microparticles while enabling consistent, large-scale manufacturing.
2Quantity of substance
If stem cells are cultured extensively to ensure consistent supply, then production volume increases, but costs and time delays increase
Solution Approach 1:
The patent applies self-service through the use of conditionally-immortalized stem cells that can self-renew and maintain themselves in culture indefinitely. Unlike traditional stem cells that require periodic derivation from fresh sources, these immortalized cells serve themselves by continuously proliferating and maintaining their therapeutic properties. This eliminates the need for repeated cell derivation, testing, and validation, thereby reducing both time delays and associated costs while ensuring consistent supply volume.
3Productivity
If conditionally-immortalised cells are used to produce microparticles, then production scalability is improved, but potential safety risks may arise
Solution Approach 1:
The patent applies dynamics through conditional immortalization, where the immortalized stem cells can be dynamically controlled between immortalized and non-immortalized states. The cells express immortalization genes only under specific induction conditions, allowing the system to switch between high-proliferation state (for scalable production) and controlled state (for safety). This dynamic control enables scalable production while mitigating safety risks associated with uncontrolled cell proliferation.
Data Source
Figure 1A~1F
Figure 2
Figure 3
AI summary
The invention is based on the finding that microparticles can be produced by conditionally- immortalised cells. The conditionally-immortalised cells may be stem cells. The Examples show the successful harvest of microparticles from conditionally immortalised neural stem cells and CD34+ cells. Conditional immortalisation provides a constant supply of clonal cells that produce microparticles such as exosomes. The conditionally immortalised cells are useful as "producer cells" for microparticles such as exosomes, which are typically harvested or isolated from the conditionally-immortalised cells.